LENZ Therapeutics, Inc. (LENZ)
(Delayed Data from NSDQ)
$18.54 USD
-0.09 (-0.48%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $18.56 +0.02 (0.11%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for LENZ Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 135 | 106 | 60 | 14 | 0 |
Income After Depreciation & Amortization | -135 | -106 | -60 | -14 | 0 |
Non-Operating Income | 11 | 5 | -10 | -55 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -125 | -101 | -71 | -68 | 0 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -125 | -101 | -71 | -68 | 0 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -125 | -101 | -71 | -68 | 0 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -131 | -105 | -60 | -13 | 0 |
Depreciation & Amortization (Cash Flow) | 4 | 1 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -135 | -106 | -60 | -14 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | NA | 7.84 | 4.13 | NA | NA |
Diluted EPS Before Non-Recurring Items | NA | -12.88 | -17.15 | NA | NA |
Diluted Net EPS (GAAP) | -15.33 | -12.88 | -17.14 | -209.45 | NA |
Fiscal Year end for LENZ Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 16.09 | 25.55 | 25.02 | 58.16 | 26.45 |
Income After SG&A, R&D, and Dept/Amort Expenses | -16.09 | -25.55 | -25.02 | -58.16 | -26.45 |
Non-Operating Income | -0.56 | 2.64 | 2.54 | 2.85 | 2.52 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -16.65 | -22.92 | -22.49 | -55.31 | -23.93 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -16.65 | -22.92 | -22.49 | -55.31 | -23.93 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -16.65 | -22.92 | -22.49 | -55.31 | -23.93 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 4.72 | NA | 8.18 | 8.11 | 7.98 |
Diluted EPS Before Non-Recurring Items | -3.53 | NA | -1.33 | -2.17 | -2.66 |
Diluted Net EPS (GAAP) | -3.53 | -2.80 | -2.73 | -6.79 | -3.01 |